证券代码：688361 证券简称：中科飞测 公告编号：2025-069 深圳中科飞测科技股份有限公司 关于预计 2025 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：本次深圳中科飞测科技股份有限公司 （以下简称"公司"）预计2025年度日常关联交易是基于公司业务发展及生产经 营需要，均由交易双方根据自愿、平等、互利的原则进行，定价公允，不存在损 害公司及股东利益，特别是中小股东利益的情形，不会对关联方形成依赖，不会 对公司主要业务的独立性造成影响。 风险提示：本次关联交易预计是基于公司自身战略发展的需要和行业前 景综合考虑，但未来可能面临市场需求、行业政策、经营管理、宏观经济等不确 定因素的影响，敬请广大投资者注意投资风险。 一、日常关联交易基本情况 （一）履行的审议程序 1、独立董事专门会议的审议意见 公司于2025年12月3日召开第二届董事会2025年第一次独立董事专门会议， 审议通过了《关于预计2025年度日常关联 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-068 深圳中科飞测科技股份有限公司 关于变更部分募集资金用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳中科飞测科技股份有限公司（以下简称"公司"）于 2025 年 12 月 3 日分别召开了第二届董事会第十八次会议和第二届监事会第十六次会议，审议通 过了《关于变更部分募集资金用途的议案》，为提升募集资金使用效率，保证募 集资金使用的规范性，结合公司实际情况，公司拟变更部分募集资金用途。该事 项不涉及关联交易，尚须提交公司股东大会审议。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2025 年 8 月 4 日出具的《关于同意深圳中 科飞测科技股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕 1640 号），公司 2024 年度向特定对象发行 A 股股票 28,571,428 股，发行价格 87.50 元/股，募集资金总额为人民币 250,000.00 万元，扣除各项发行费用（不含 增值税）人民币 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-071 深圳中科飞测科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 12 月 19 日 14 点 00 分 召开地点：深圳市南山区深圳国际创新谷 8 栋 A 座 24 楼公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 19 日 至2025 年 12 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年12月19日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-065 深圳中科飞测科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）审议通过《关于使用募集资金置换预先投入募投项目及支付发行费用 的自筹资金的议案》 监事会认为：公司本次使用募集资金置换预先投入募投项目及支付发行费用 的自筹资金，不存在变相改变募集资金用途和损害股东利益的情况，不会影响募 集资金投资项目的正常进行。监事会同意本次使用募集资金置换预先投入募投项 目及支付发行费用的自筹资金的事项。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《深圳中科飞测科技股份有限公司关于使用募集资金置换预先投入募投项目及 支付发行费用的自筹资金的公告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案无需提交股东大会审议。 （二）审议通过《关于使用部分闲置募集资金临时补充流动资金的议案》 一、 监事会会议召开情况 深圳中科飞测科技股份有限公司（以下简称"公司"）第二届 ...

Core Insights - The A-share private placement market is experiencing significant participation from public funds in 2025, with 33 fund companies involved and a total allocation amounting to 17.3 billion yuan, representing a 140% increase compared to the entire year of 2024 [1][5][8] Group 1: Market Participation - Public funds have shown a marked increase in enthusiasm for private placements, with a total allocation of 17.3 billion yuan in 2025, up from 7.2 billion yuan in 2024, indicating a growth of over 100 billion yuan [5][6] - Leading public fund companies include E Fund with 3.687 billion yuan, followed by GF Fund, Fortune Fund, and China Universal Fund with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [5][6] Group 2: Investment Focus - The investment focus of public funds is heavily concentrated in hard technology sectors, particularly in semiconductors, artificial intelligence, and innovative pharmaceuticals, reflecting a strong alignment with the ongoing "technology bull" market [6][8] - Notable allocations in the electronics sector reached 7.45 billion yuan, while the biopharmaceutical sector saw allocations of 5.6 billion yuan, targeting companies like Cambricon, Chipone, and innovative drug firms [6][8] Group 3: Market Drivers - The resurgence of private placements is driven by three main factors: policy incentives, a safety margin due to discount pricing, and significant profit potential observed by participating public funds [8] - The current trend shows increased participation, improved returns, and a strong focus on technology and high-end manufacturing sectors, with expectations for continued growth in public fund involvement in private placements [8]

Core Insights - The A-share private placement market is experiencing significant growth, with public funds participating deeply in 2025, leading to a total allocation of 17.3 billion yuan, a 140% increase compared to the entire year of 2024 [1][3][4] Group 1: Market Participation - A total of 33 public fund companies have participated in private placements, with the leading fund, E Fund, securing 3.687 billion yuan [3][4] - Other notable funds include GF Fund, Fortune Fund, and China Universal Fund, with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [3][4] - The trend shows a competitive landscape where larger funds dominate, but smaller funds are also actively participating [3][4] Group 2: Investment Focus - Public funds are primarily focusing on hard technology sectors, particularly semiconductors, artificial intelligence, and innovative pharmaceuticals, reflecting a strong alignment with industry trends [4][5] - The electronic industry received 7.45 billion yuan in allocations, while the biopharmaceutical sector saw 5.6 billion yuan, with key companies like Cambricon, Chipone, and Bairi Tianheng being major targets [4][5] Group 3: Market Drivers - The resurgence in private placements is driven by three main factors: policy incentives, built-in discount safety, and significant profit potential [7] - The favorable policy environment encourages capital market support for the real economy, especially in technology sectors [7] - The overall performance of public funds in private placements has been strong, further motivating institutional participation [7]

Core Insights - The A-share private placement market is experiencing significant participation from public funds in 2025, with a total allocation amount reaching 17.3 billion yuan, marking a 140% increase compared to the entire year of 2024 [1][7]. Group 1: Market Participation - A total of 33 public fund companies have participated in private placements in 2025, with the leading company, E Fund, securing 3.687 billion yuan [3][10]. - Other notable participants include GF Fund, Fortune Fund, and China Universal Fund, with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [3][10]. - The trend shows a competitive landscape where larger firms dominate, but smaller firms are also actively participating [3][10]. Group 2: Investment Focus - Public fund investments are heavily concentrated in hard technology sectors, particularly semiconductors, artificial intelligence, and innovative pharmaceuticals [5][12]. - In the electronics sector, public funds have allocated 7.45 billion yuan, while in the biopharmaceutical sector, the allocation reached 5.6 billion yuan [5][13]. - Key companies receiving significant allocations include Baile Tianheng, Cambricon, Chipone, and Dizhe Pharmaceutical, each exceeding 1 billion yuan in public fund allocations [5][14]. Group 3: Drivers of Growth - The resurgence in private placements is driven by three main factors: policy incentives, a safety margin from discounts, and significant profit potential [6][14]. - The favorable policy environment encourages capital market support for the real economy, particularly in technology sectors [6][14]. - The overall performance of public funds in private placements has been strong, further motivating institutional participation [6][14].

Group 1 - The semiconductor sector showed strength on November 28, 2025, with the Shanghai Stock Exchange Sci-Tech Innovation Board Chip Index rising by 1.22% [1] - Key stocks such as Jinghe Integrated rose by 11.32%, Tuojing Technology by 6.55%, and Tianyue Advanced by 6.13% [1] - The Chinese semiconductor industry is expected to see the chip design sector exceed 1 trillion yuan by 2030, indicating strong long-term growth potential [1] Group 2 - Dongguan Securities forecasts that artificial intelligence will remain the main innovation line in the technology sector through 2026, benefiting multiple segments including computing power, storage, equipment, and advanced packaging [1] - The top ten weighted stocks in the Sci-Tech Innovation Board Chip Index account for 60.55% of the index, with major companies including Haiguang Information, Cambricon, and SMIC [1] Group 3 - The Sci-Tech Chip ETF (588200) tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Chip Index, providing a convenient tool for investing in the chip sector [2] - Investors without stock accounts can access domestic chip investment opportunities through the Sci-Tech Chip ETF Linked Fund (017470) [3]

Group 1 - The semiconductor equipment sector experienced a notable surge on November 28, with companies such as Jingyi Equipment and Tuojing Technology rising over 5% [1] - Other companies in the sector, including Zhongke Feicai, Jingsheng Shares, and Huahai Qingke, also saw increases in their stock prices [1]

11月28日，中科飞测涨5.19%，截至发稿，报121.13元/股，成交1.76亿元，换手率0.60%，总市值424.15 亿元。 资料显示，深圳中科飞测科技股份有限公司位于广东省深圳市龙华区观澜街道观光路银星科技园1301 号，成立日期2014年12月31日，上市日期2023年5月19日，公司主营业务涉及检测和量测两大类集成电 路专用设备的研发、生产和销售。主营业务收入构成为：检测设备60.72%，量测设备36.40%，服务及 其他2.88%。 截至发稿，冯杰波累计任职时间1年16天，现任基金资产总规模3.7亿元，任职期间最佳基金回报 76.96%， 任职期间最差基金回报-10.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，东财基金旗下1只基金重仓中科飞测。东财时代优选混合发起式A（017857）三季度持有股 数6500股，占基金净值比例为3.98%，位居第七大重仓股。根据测算，今日浮盈赚取约3.89万元。 东财时代优选混合发起式 ...